Merck KGaA Signs Definitive Deal to Acquire Rapid Micro Biosystems
RPID sits 16% above its 52-week low of $0.58 on light trading volume (0.4× avg).
Summary
Rapid Micro Biosystems signed a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany, in an all-cash transaction at 75 cents per share, per Dow Jones Newswires. That is a terminal event for the micro-cap: the stock trades at $0.675 with a market value of roughly $33 million, so a takeout puts a hard floor under the shares and ends the standalone story. The company was burning cash — reserves fell to $14.7 million in Q2 2026 despite 11% revenue growth and a record 15% gross margin — which makes a strategic buyer the most plausible exit. In the third quarter, revenue rose 21.6% to $9.5 million while the adjusted EBITDA loss was $7.9 million, and the company withdrew its 2026 guidance due to the Merck acquisition.
At the time of this announcement, RPID was trading at $0.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $32.7M. The 52-week trading range was $0.58 to $4.94. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.